Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, March 11, 2019 at 4:00 PM to 4:30 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 05.03.15 in Vol 4, No 1 (2015): Jan-Mar

This paper is in the following e-collection/theme issue:

Works citing "Preferred Features of Oral Treatments and Predictors of Non-Adherence: Two Web-Based Choice Experiments in Multiple Sclerosis Patients"

According to Crossref, the following articles are citing this article (DOI 10.2196/ijmr.3776):

(note that this is only a small subset of citations)

  1. Fox E, Vieira MC, Johnson K, Peeples M, Bensimon AG, Signorovitch J, Herrera V. Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis. Journal of the Neurological Sciences 2019;398:163
    CrossRef
  2. Wynn DR. Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use. Multiple Sclerosis International 2019;2019:1
    CrossRef
  3. Rahimi F, Rasekh HR, Abbasian E, Peiravian F, Etemadifar M, Ashtari F, Sabzghabaee AM, Amirsadri MR, Weber MS. Patient preferences for Interferon-beta in Iran: A discrete choice experiment. PLOS ONE 2018;13(3):e0193090
    CrossRef
  4. Kremer IEH, Evers SMAA, Jongen PJ, Hiligsmann M. Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: A best-worst scaling. Health Expectations 2018;21(1):171
    CrossRef
  5. Webb EJD, Meads D, Eskyte I, King N, Dracup N, Chataway J, Ford HL, Marti J, Pavitt SH, Schmierer K, Manzano A. A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis. The Patient - Patient-Centered Outcomes Research 2018;11(4):391
    CrossRef
  6. Poulos C, Kinter E, van Beek J, Christensen K, Posner J. PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE. International Journal of Technology Assessment in Health Care 2018;34(4):425
    CrossRef
  7. Ravoire S, Lang M, Perrin E, Audry A, Bilbault P, Chekroun M, Demerville L, Escudier T, Guéroult-Accolas L, Guillot C, Malbezin M, Maugendre P, Micallef J, Molimard M, Montastruc F, Pierron E, Reichardt L, Thiessard F. Advantages and limitations of online communities of patients for research on health products. Therapies 2017;72(1):135
    CrossRef
  8. Bottomley C, Lloyd A, Bennett G, Adlard N. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis. Journal of Medical Economics 2017;20(8):863
    CrossRef
  9. Ravoire S, Lang M, Perrin E, Audry A, Bilbault P, Chekroun M, Demerville L, Escudier T, Guéroult-Accolas L, Guillot C, Malbezin M, Maugendre P, Micallef J, Molimard M, Montastruc F, Pierron E, Reichardt L, Thiessard F. Intérêts et limites des communautés virtuelles de patients pour la recherche sur les produits de santé. Therapies 2017;72(1):125
    CrossRef
  10. Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. Journal of Managed Care & Specialty Pharmacy 2017;23(8):844
    CrossRef
  11. Mansfield C, Thomas N, Gebben D, Lucas M, Hauber AB. Preferences for Multiple Sclerosis Treatments. International Journal of MS Care 2017;19(4):172
    CrossRef
  12. Hincapie AL, Penm J, Burns CF. Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis. Journal of Managed Care & Specialty Pharmacy 2017;23(8):822
    CrossRef
  13. Kremer IEH, Evers SMAA, Jongen PJ, van der Weijden T, van de Kolk I, Hiligsmann M, Aktas O. Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling. PLOS ONE 2016;11(11):e0164862
    CrossRef
  14. Lin P, Saret CJ, Neumann PJ, Sandberg EA, Cohen JT. Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study. PharmacoEconomics 2016;34(12):1255
    CrossRef